<DOC>
	<DOCNO>NCT00777699</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability XL765 combination erlotinib ( TarcevaÂ® ) subject solid tumor . XL765 new chemical entity inhibit kinase PI3K mTOR . In preclinical study , inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell , whereas inactivation mTOR show inhibit growth tumor cell . Erlotinib orally administer inhibitor EGFR ( also know HER1 ) tyrosine kinase . It approve FDA single agent treatment patient locally advanced metastatic non-small-cell lung cancer ( NSCLC ) failure least one prior chemotherapy regimen combination gemcitabine first line treatment patient locally advance , unresectable metastatic pancreatic cancer .</brief_summary>
	<brief_title>Safety Study XL765 ( SAR245409 ) Combination With Erlotinib Adults With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Confirmed diagnosis : Advanced solid tumor longer respond therapy OR Advanced metastatic NSCLC previously treat erlotinib gefitinib ECOG Performance Status 01 Adequate organ bone arrow function define hematological serum chemistry limit At least 18 year old Both men woman must practice adequate contraception Informed consent Restriction therapies/medications within specific timeframes prior enrollment study include prior therapy PI3K , cytotoxic chemotherapy , biologic agent , nitrosoureas mitomycin C , smallmolecule kinase inhibitor , noncytotoxic hormonal agent Erlotinib intolerant Taking oral corticosteroid chronically &gt; 1 mg/day warfarin Not recover toxic effect prior therapy History diabetes mellitus HgbA1c &gt; 7 % Uncontrolled intercurrent illness Pregnant breastfeeding Congestive heart failure , unstable angina , myocardial infarction within 3 month enter study . HIV positive Diagnosis another malignancy may exclude subject study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>NSCLC</keyword>
</DOC>